RESUMEN
The prognostic value of angiogenic factors in newly pregnant women with obstetric antiphospholipid syndrome (oAPS) has not been documented. We observed 513 oAPS who experienced three consecutive spontaneous abortions before the 10th week of gestation or one fetal loss at or beyond the 10th week. We assessed the plasma concentrations of the proangiogenic factor placenta growth factor (PIGF) and of the antiangiogenic factor soluble fms-like tyrosine kinase-1 on the eve and on the 4th day of the low-molecular weight heparin-low-dose aspirin treatment. Placenta growth factor and fms-like tyrosine kinase-1 plasma concentrations showed marked increases. Treatment-associated variations of PIGF and of soluble fms-like tyrosine kinase-1 were antagonist risk factors for placenta-mediated complications (PMC) and for severe PMC, for fetal death, stillbirth and neonatal death. The ratio between PIGF increase and soluble fms-like tyrosine kinase-1 was a summary variable whose best cut-off values (1.944.10-2) had high negative predictive values for PMC (0.918) and may be used to help rule out the development of PMC in evolutive pregnancies after 19 completed weeks. The early variations of PIGF and soluble fms-like tyrosine kinase-1 concentrations in newly pregnant oAPS may help to detect patients at low risk of PMC. (clinicaltrials.gov identifier: 02855047).
Asunto(s)
Síndrome Antifosfolípido/sangre , Proteínas de la Membrana/sangre , Complicaciones del Embarazo/sangre , Primer Trimestre del Embarazo/sangre , Receptor 1 de Factores de Crecimiento Endotelial Vascular/sangre , Adolescente , Adulto , Síndrome Antifosfolípido/diagnóstico , Síndrome Antifosfolípido/tratamiento farmacológico , Aspirina/uso terapéutico , Femenino , Fibrinolíticos/uso terapéutico , Heparina de Bajo-Peso-Molecular/uso terapéutico , Humanos , Placenta/metabolismo , Embarazo , Complicaciones del Embarazo/diagnóstico , Complicaciones del Embarazo/tratamiento farmacológico , Resultado del Embarazo , Adulto JovenRESUMEN
The incidence of pregnancy outcomes in women with constitutive thrombophilia is uncertain. We observed women with no history of thrombotic events (nonthrombotic), who had experienced 3 consecutive spontaneous abortions before the 10th week of gestation or 1 fetal death at or beyond the 10th week of gestation. We compared the frequencies of complications during a new pregnancy attempt among women carrying the F5 rs6025 or F2 rs1799963 polymorphism (n = 279; low-molecular-weight heparin [LMWH] treatment during pregnancy only in case of prior fetal death), and women with negative thrombophilia screening results as control women (n = 796; no treatment). Among women with prior recurrent abortions, thrombophilic women were at increased risk for fetal death. Among women with prior fetal death, thrombophilic women experienced less fetal death recurrences, less preterm births and preeclampsia, and more live births as they were treated with LMWH. In nonthrombotic F5 rs6025 or F2 rs1799963 heterozygous women with prior pregnancy loss, fetal loss may indicate a clinical subgroup in which future therapeutic randomized controlled trials testing the effect of LMWH prophylaxis are required in priority.
Asunto(s)
Aborto Habitual/epidemiología , Complicaciones Hematológicas del Embarazo/epidemiología , Trombofilia/complicaciones , Trombofilia/epidemiología , Adolescente , Adulto , Factor V/genética , Femenino , Muerte Fetal , Fibrinolíticos/uso terapéutico , Heparina de Bajo-Peso-Molecular/uso terapéutico , Humanos , Incidencia , Polimorfismo Genético , Embarazo , Resultado del Embarazo , Protrombina/genética , Adulto JovenRESUMEN
The incidence of pregnancy outcomes for women with the purely obstetric form of antiphospholipid syndrome (APS) treated with prophylactic low-molecular-weight heparin (LMWH) plus low-dose aspirin (LDA) has not been documented. We observed women without a history of thrombosis who had experienced 3 consecutive spontaneous abortions before the 10th week of gestation or 1 fetal loss at or beyond the 10th week. We compared the frequencies of complications during new pregnancies between treated women with APS (n = 513; LMWH + LDA) and women negative for antiphospholipid antibodies as controls (n = 791; no treatment). Among APS women, prior fetal loss was a risk factor for fetal loss, preeclampsia (PE), premature birth, and the occurrence of any placenta-mediated complication. Being positive for anticardiolipin immunoglobulin M antibodies was a risk factor for any placenta-mediated complication. Among women with a history of recurrent abortion, APS women were at a higher risk than other women of PE, placenta-mediated complications, and neonatal mortality. Among women with prior fetal loss, LMWH + LDA-treated APS women had lower pregnancy loss rates but higher PE rates than other women. Improved therapies, in particular better prophylaxis of late pregnancy complications, are urgently needed for obstetric APS and should be evaluated according to the type of pregnancy loss.
Asunto(s)
Anticuerpos Antifosfolípidos/sangre , Síndrome Antifosfolípido/epidemiología , Síndrome Antifosfolípido/terapia , Complicaciones del Embarazo/epidemiología , Complicaciones del Embarazo/terapia , Aborto Habitual/epidemiología , Aborto Espontáneo/epidemiología , Adolescente , Adulto , Anticuerpos Anticardiolipina/sangre , Enoxaparina/uso terapéutico , Femenino , Fibrinolíticos/uso terapéutico , Humanos , Inmunoglobulina M/química , Placenta/metabolismo , Embarazo , Resultado del Embarazo , Pronóstico , Factores de Riesgo , Adulto JovenRESUMEN
The incidence of thrombosis in the purely obstetric form of antiphospholipid syndrome is uncertain. We performed a 10-year observational study of 1592 nonthrombotic women who had experienced 3 consecutive spontaneous abortions before the 10th week of gestation or 1 fetal death at or beyond the 10th week of gestation. We compared the frequencies of thrombotic events among women positive for antiphospholipid Abs (n = 517), women carrying the F5 6025 or F2 rs1799963 polymorphism (n = 279), and women with negative thrombophilia screening results (n = 796). The annual rates of deep vein thrombosis (1.46%; range, 1.15%-1.82%), pulmonary embolism (0.43%; range, 0.26%-0.66%), superficial vein thrombosis (0.44%; range, 0.28%-0.68%), and cerebrovascular events (0.32%; range, 0.18%-0.53%) were significantly higher in aPLAbs women than in the other groups despite low-dose aspirin primary prophylaxis. Women carrying 1 of the 2 polymorphisms did not experience more thrombotic events than women who screened negative for thrombophilia. Lupus anticoagulant was a risk factor for unprovoked proximal and distal deep and superficial vein thrombosis and women in the upper quartile of lupus anticoagulant activity had the highest risk. Despite data suggesting that aPLAbs may induce pregnancy loss through nonthrombotic mechanisms, women with purely obstetric antiphospholipid syndrome are at risk for thrombotic complications.
Asunto(s)
Aborto Espontáneo/epidemiología , Síndrome Antifosfolípido/epidemiología , Factor V/genética , Polimorfismo Genético/genética , Complicaciones del Embarazo/epidemiología , Protrombina/genética , Trombosis/epidemiología , Aborto Espontáneo/etiología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Anticuerpos Antifosfolípidos/sangre , Síndrome Antifosfolípido/complicaciones , Síndrome Antifosfolípido/genética , Femenino , Estudios de Seguimiento , Francia/epidemiología , Humanos , Incidencia , Inhibidor de Coagulación del Lupus/uso terapéutico , Masculino , Persona de Mediana Edad , Embarazo , Complicaciones del Embarazo/etiología , Estudios Prospectivos , Factores de Riesgo , Trombofilia/epidemiología , Trombofilia/etiología , Trombosis/etiología , Trombosis de la Vena/epidemiología , Trombosis de la Vena/etiología , Adulto JovenRESUMEN
BACKGROUND: Preeclampsia is a frequent complication of pregnancy and a leading cause of perinatal mortality. Both genetic and environmental risk factors have been identified. Lipid metabolism, particularly cholesterol metabolism, is associated with this disease. Liver X receptors alpha (NR1H3, also known as LXRalpha) and beta (NR1H2, also known as LXRbeta) play a key role in lipid metabolism. They belong to the nuclear receptor superfamily and are activated by cholesterol derivatives. They have been implicated in preeclampsia because they modulate trophoblast invasion and regulate the expression of the endoglin (CD105) gene, a marker of preeclampsia. The aim of this study was to investigate associations between the NR1H3 and NR1H2 genes and preeclampsia. METHODS: We assessed associations between single nucleotide polymorphisms of NR1H3 (rs2279238 and rs7120118) and NR1H2 (rs35463555 and rs2695121) and the disease in 155 individuals with preeclampsia and 305 controls. Genotypes were determined by high-resolution melting analysis. We then used a logistic regression model to analyze the different alleles and genotypes for those polymorphisms as a function of case/control status. RESULTS: We found no association between NR1H3 SNPs and the disease, but the NR1H2 polymorphism rs2695121 was found to be strongly associated with preeclampsia (genotype C/C: adjusted odds ratio, 2.05; 95% CI, 1.04-4.05; p = 0.039 and genotype T/C: adjusted odds ratio, 1.85; 95% CI, 1.01-3.42; p = 0.049). CONCLUSIONS: This study provides the first evidence of an association between the NR1H2 gene and preeclampsia, adding to our understanding of the links between cholesterol metabolism and this disease.
Asunto(s)
Receptores Nucleares Huérfanos/genética , Polimorfismo Genético , Preeclampsia/genética , Adulto , Estudios de Casos y Controles , Femenino , Predisposición Genética a la Enfermedad , Técnicas de Genotipaje/métodos , Humanos , Receptores X del Hígado , Polimorfismo de Nucleótido Simple , Embarazo , Adulto JovenRESUMEN
OBJECTIVES: Case reports describe neuropsychiatric manifestations associated with antiphospholipid antibodies (aPlAbs). In patients sharing the same symptoms fulfilling the antiphospholipid syndrome (APS) clinical criteria, the prevalence of common mental disorders has, however, never been studied. METHODS: We observed women with three consecutive abortions before the 10th week of gestation or one foetal loss at or beyond the 10th week. We compared the prevalence of common psychiatric disorders detected through screening using the Mini International Neuropsychiatric Interview, 10 years after inclusion, in women with APS (n = 506), women negative for aPlAbs but carrying the F5rs6025 or F2rs1799963 thrombogenic polymorphism (n = 269), and women with negative thrombophilia screening results as controls (n = 764). RESULTS: Similar prevalence values were obtained for controls and women bearing one of the two thrombogenic polymorphisms. Women with APS more frequently had mood disorders (relative risk (RR) 1.57 (1.262-1.953), P = .0001) and anxiety (RR 1.645 (1.366-1.979), P < .0001). Within the APS group, lupus anticoagulant (LA) and anti-ß2GP1 IgG, or triple positivity, were strong risk factors for mood disorders. CONCLUSIONS: Women with obstetric APS have a higher risk of positive screening for common mental disorders than women without APS.
Asunto(s)
Aborto Espontáneo , Anticuerpos Antifosfolípidos/sangre , Síndrome Antifosfolípido , Trastornos de Ansiedad , Trastornos del Humor , Trombofilia , Aborto Habitual/sangre , Aborto Habitual/epidemiología , Aborto Habitual/inmunología , Aborto Espontáneo/sangre , Aborto Espontáneo/epidemiología , Aborto Espontáneo/inmunología , Adulto , Síndrome Antifosfolípido/sangre , Síndrome Antifosfolípido/epidemiología , Síndrome Antifosfolípido/inmunología , Trastornos de Ansiedad/sangre , Trastornos de Ansiedad/epidemiología , Trastornos de Ansiedad/inmunología , Femenino , Estudios de Seguimiento , Humanos , Incidencia , Persona de Mediana Edad , Trastornos del Humor/sangre , Trastornos del Humor/epidemiología , Trastornos del Humor/inmunología , Embarazo , Prevalencia , Trastornos Psicóticos/sangre , Trastornos Psicóticos/epidemiología , Trastornos Psicóticos/inmunología , Trastornos Relacionados con Sustancias/sangre , Trastornos Relacionados con Sustancias/epidemiología , Trastornos Relacionados con Sustancias/inmunología , Trombofilia/sangre , Trombofilia/epidemiología , Trombofilia/inmunologíaRESUMEN
Antiphospholipid antibodies (APLAbs) are generally considered as risk factors for foetal death, for premature birth ≤34weeks due to severe pre-eclampsia or severe placental insufficiency and for recurrent consecutive spontaneous abortions <10weeks. Among these three obstetrical morbidities, only the first one is however not regularly questioned. The coexistence of an inflammatory disease and/or of thrombotic manifestations increases the obstetrical risks. Among the three criteria APLAbs, i.e. lupus anticoagulant (LA), anticardiolipin (aCL) Abs, anti-ß2 glycoprotein-I (aß2GP1)Abs, LA seems the more widely associated to clinical risks, the clinical impact of aß2GP1Abs is progressively defined and the pejorative impact of triple positivity is still discussed. High quality prospective multicentric epidemiological studies are still awaited. The identification of predictors of pregnancy outcome is necessary to streamline the design and use of new treatments acting on pathophysiological molecular targets.